Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05658523 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

COVID-19 Booster Study in Healthy Adults in Australia

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Jan 2, 2026 Enrollment target: 497 to 496 · Secondary endpoints revised (10)v8 Show 2 more changesShow less
    • Enrollment target: 497 to 496
    • Secondary endpoints revised (10)

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date changed from estimate of Oct 2024 to Oct 13, 2024 Completion date: Oct 2024 to Apr 2026 · Secondary endpoints revised (10) · Primary endpoints revised (2)v7 Show 3 more changesShow less
    • Completion date: Oct 2024 to Apr 2026
    • Secondary endpoints revised (10)
    • Primary endpoints revised (2)

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Sep 6, 2023 to Oct 2024 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 600 to confirmed 497 · Completion date: Aug 6, 2024 to Oct 2024 · 1 morev6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 600 to confirmed 497
    • Completion date: Aug 6, 2024 to Oct 2024
    • Site details revised
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 31, 2023 to Feb 28, 2023 · Site details revisedv5 Show 2 more changesShow less
    • Start date changed from estimate of Mar 31, 2023 to Feb 28, 2023
    • Site details revised
  5. Start date: Feb 6, 2023 to Mar 31, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Sep 30, 2023 to Sep 6, 2023 Completion date: Aug 30, 2024 to Aug 6, 2024 · Start date: Feb 28, 2023 to Feb 6, 2023v3 Show 2 more changesShow less
    • Completion date: Aug 30, 2024 to Aug 6, 2024
    • Start date: Feb 28, 2023 to Feb 6, 2023
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a double-blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy adults in Australia.
Trial Details
NCT Number NCT05658523
Lead Sponsor Murdoch Childrens Research Institute
Collaborators: Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity
Conditions COVID-19
Enrollment 496 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov